It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- Headquartered in San Francisco CA, Calithera is a clinical-stage biotech, focusing on developing preferential anti-cancer therapies by disrupting cellular metabolic pathways
- Lead asset = Telaglenastat is in P2 of development in combo with Merck’s (MRK) Keytruda as front-line treatment for patients with stage IV non-squamous non-small cell lung cancer (NSCLC)
- Second most advanced asset = CB-1158 is in P2 across three diff cancer indication
- Third asset = CD-280 is in P1b of development for cystic fibrosis (CF)